Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Der Internist|June 14, 2008
[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?]A Seeringer, J KirchheinerBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|October 3, 2006
[State of the art of pharmacogenetic diagnostics in drug therapy]J Kirchheiner, A Seeringer, J BrockmöllerMolecular Psychiatry|April 7, 2010
CYP2D6 in the brain: genotype effects on resting brain perfusionJ Kirchheiner, A Seeringer, A L Godoy, et al.Diabetes, Obesity & Metabolism|October 28, 2010
Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabeticsA Seeringer, S Parmar, A Fischer, et al.Clinical Pharmacology and Therapeutics|January 19, 2008
CYP2D6 phenotype prediction from genotype: which system is the best?J KirchheinerClinical Pharmacology and Therapeutics|January 30, 2007
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approachU Fuhr, A Jetter, J KirchheinerClinical Pharmacology and Therapeutics|March 3, 2007
Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effectsJ Brockmöller, I Meineke, J KirchheinerPharmacopsychiatry|April 13, 2000
Healthy outcome under olanzapine treatment in a pregnant womanJ Kirchheiner, A Berghöfer, D Bolk-WeischedelPharmacogenomics|March 21, 2001
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatmentJ Brockmöller, J Kirchheiner, C Meisel, et al.The Pharmacogenomics Journal|June 6, 2007
The clinical role of genetic polymorphisms in drug-metabolizing enzymesD Tomalik-Scharte, A Lazar, U Fuhr, et al.Pageof 4